Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Adaptimmune Therapeutics Plc

ADAP
Current price
0.98 USD +0.057 USD (+6.15%)
Last closed 0.9 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 302 840 960 USD
Yield for 12 month -30.73 %
1Y
3Y
5Y
10Y
15Y
ADAP
21.11.2021 - 28.11.2021

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Address: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.5 USD

P/E ratio

Dividend Yield

Current Year

+60 514 653 USD

Last Year

+27 148 000 USD

Current Quarter

+233 009 USD

Last Quarter

+7 319 000 USD

Current Year

+50 657 594 USD

Last Year

-100 578 000 USD

Current Quarter

-2 641 783 USD

Last Quarter

+4 443 784 USD

Key Figures ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -128 198 000 USD
Operating Margin TTM -21582.68 %
PE Ratio
Return On Assets TTM -28.22 %
PEG Ratio 0.11
Return On Equity TTM -187.61 %
Wall Street Target Price 3.5 USD
Revenue TTM 60 281 000 USD
Book Value 0.17 USD
Revenue Per Share TTM 0.3 USD
Dividend Share
Quarterly Revenue Growth YOY -97.9 %
Dividend Yield
Gross Profit TTM -100 578 000 USD
Earnings Share -0.54 USD
Diluted Eps TTM -0.54 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -188.9 %

Dividend Analytics ADAP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date 30.03.2018

Stock Valuation ADAP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.8989
Price Sales TTM 4.9178
Enterprise Value EBITDA -1.3631
Price Book MRQ 7.5026

Financials ADAP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ADAP

For 52 weeks

0.42 USD 2.05 USD
50 Day MA 1.41 USD
Shares Short Prior Month 3 112 390
200 Day MA 0.89 USD
Short Ratio 1.64
Shares Short 3 197 059
Short Percent 2.97 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics